Answers are grounded in this paper and cite their sources.
Breast cancer (BC) remains the most commonly diagnosed malignancy among women worldwide. Cucurbitacin B (CB), a plant-derived triterpenoid from Trichosanthes cucumerina L. and resveratrol (RV), a natural stilbene compound isolated from grapes, peanuts, and berries, have demonstrated potent anticancer activities against various cancers, including breast cancer. Both compounds have also shown synergistic interactions with conventional chemotherapeutics and other plant-derived natural compounds. Given their distinct mechanisms of action, the combination of CB and RV may potentiate anti-breast cancer activity through shared or combined different mechanistic pathways. This study aimed to evaluate the novel CB: RV combination for synergistic enhancement of anti-breast tumor efficacy both in vitro and in vivo. The synergistic effect of CB: RV combinations was evaluated in MDA-MB-231 and MCF-7 breast cancer cells in vitro. Their effects and mechanisms on cell cycle and apoptosis were investigated by flow cytometry and Western blotting. In vivo antitumor efficacy was assessed using MDA-MB-231-Luc xenografted mice, monitored via an in vivo imaging system. The CB: RV combination at proper ratios exhibited synergistic cytotoxicity against both breast cancer cell lines, significantly reducing cell viability and enhancing apoptosis, particularly in MDA-MB-231 cells. The combination also allowed a reduction in the effective dose of CB. In MDA-MB-231 cells, the synergistic effects were primarily attributed to the induction of the Sub G1 population and apoptosis mediated through DNA damage and caspase-dependent mechanisms. Meanwhile, in MCF-7 cells, the combination induced apoptosis associated with RV-induced S phase accumulation and enhanced DNA damage, with a potential trend toward modulating apoptotic proteins. In vivo, the combination suppressed tumor growth and reduced tumor burden in xenograft mice over a 7-week treatment period. These findings highlight the potential of CB and RV combination therapy as an alternative strategy for breast cancer treatment, offering an enhanced therapeutic benefit through multi-targeted mechanisms.
No takes yet. Share an insight, caveat, or question.
Sakchaisri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: